Blockade of PD-1 can prevent the interaction of innate T-cell PD-1 to tumor cell-expressed PD-L1, thereby re-establishing T-cell anti-tumor immunity and immune system targeting and thus improving immune-targeted destruction of malignant cells [11]. The gene discussed is PDCD1; the disease is neoplasm.